Thrombogenicity

AstriVax Strengthens Leadership Team by Welcoming Chief Development Officer (CDO) Dr. Mathieu Peeters and Chief Financial Officer (CFO) Barbara Freitag

Retrieved on: 
Tuesday, October 10, 2023

Dr. Mathieu Peeters brings an extensive clinical vaccine development track record from his senior roles at GSK Vaccines.

Key Points: 
  • Dr. Mathieu Peeters brings an extensive clinical vaccine development track record from his senior roles at GSK Vaccines.
  • Barbara Freitag joins AstriVax as an accomplished CFO in the biotech sector.
  • Leuven, Belgium, October 10, 2023 – AstriVax is pleased to announce that Dr. Mathieu Peeters and Barbara Freitag have joined the company’s leadership team as Chief Development Officer and Chief Financial Officer, respectively.
  • With AstriVax soon entering into clinical stage, I am excited that Mathieu has joined us as CDO to steer our clinical vaccine development.

IPA Announces Board Refreshment

Retrieved on: 
Tuesday, September 5, 2023

IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an advanced biotherapeutic research and technology company, is pleased to announce that further to its news release dated August 9, 2023, it has appointed, in its search for optimal Board composition, Barry A. Springer, Dirk Witters and Chris Buyse to the Board of Directors of the Company.

Key Points: 
  • IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an advanced biotherapeutic research and technology company, is pleased to announce that further to its news release dated August 9, 2023, it has appointed, in its search for optimal Board composition, Barry A. Springer, Dirk Witters and Chris Buyse to the Board of Directors of the Company.
  • The appointees will add complementary skills to the Board's skill matrix, and underline IPA’s commitment to the optimal Board composition.
  • The appointment of Messrs. Springer, Witters and Buyse and additional refreshment at the near term Annual General Meeting provides IPA’s Board with experience and expertise required for IPA to take its next steps and maximize value for shareholders."
  • Forward-looking information contained in this news release includes but is not limited to the expected results of the appointment of the three new directors to the Board, and Mr. Smith’s resignation from the Board.

Celularity Tissue Factor Gene Knockout of Allogeneic Stromal Cells Significantly Lowers Thrombotic Effects; Study Highlights Critical Importance of Gene Editing Capability

Retrieved on: 
Thursday, June 1, 2023

FLORHAM PARK, N.J., June 01, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, announced today the online publication of preclinical data in Cytotherapy, the official journal of the International Society of Cell and Gene Therapy (ISCT).

Key Points: 
  • The paper, “Characterization of CRISPR/Cas9-edited human placental allogenic stromal cells with low tissue factor expression and reduced thrombotic effects,” (Huang, et al.
  • )1 examined methods to reduce the tissue factor expressed by allogeneic stromal cells (ASCs), which has been regarded as a safety concern in clinical applications as it may trigger thrombosis when ASCs are administered intravenously.
  • Thrombogenic risk has been identified in association with intravenous administration of mesenchymal stem cells (MSCs), both allogeneic and autologous.
  • These cells express procoagulant activity linked to the expression of tissue factor that, when in contact with blood, initiates coagulation.

Intravitreal Injectables Global Market Report 2022: Rising Prevalence of Diabetes Fuels Sector Growth - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 25, 2023

The "Intravitreal Injectables Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2022 to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Intravitreal Injectables Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2022 to 2030" report has been added to ResearchAndMarkets.com's offering.
  • The Intravitreal injectables market will be showcasing stable growth at a compound annual growth rate (CAGR) of 4.8% during the forecast period from 2022 to 2030.
  • In the present situation North America is accountable for 37% market share in the regional segment for Intravitreal injectables market.
  • Rising prevalence of eye disorders and affordable reimbursement scenario drive the market growth in North America.

DGAP-News: Andera Partners strengthens its Life Sciences team with a new partner

Retrieved on: 
Thursday, July 7, 2022

PARIS, JULY 7, 2022 - Andera Partners strengthens its organization by welcoming Jan Van den Bossche as a partner within Andera Life Sciences, its team specialized in innovative therapeutics and medical devices.

Key Points: 
  • PARIS, JULY 7, 2022 - Andera Partners strengthens its organization by welcoming Jan Van den Bossche as a partner within Andera Life Sciences, its team specialized in innovative therapeutics and medical devices.
  • Jan Van den Bossche, partner at Andera Life Sciences, says: "I am very pleased to join the Andera Life Sciences team, one of the most renowned European funds in the sector.
  • The Andera Life Sciences team is now composed of 15 professionals including 5 partners and 3 venture partners.
  • Its teams manage almost 3.6 billion in investments in life sciences (Andera Life Sciences), growth and buyout capital (Andera MidCap, Andera Expansion, Andera Croissance, Andera Co-Invest), sponsorless transactions (Andera Acto) and ecological transition (Andera Infra).

AAVantgarde Bio appoints Ram Palanki as Chairman of its Board of Directors

Retrieved on: 
Friday, April 1, 2022

MILAN, ITALY / ACCESSWIRE / March 31, 2022 / AAVantgarde Bio , a Milan-based biotechnology start-up that is developing gene therapies for inherited retinal disorders based on Adeno-Associated Viral (AAV) vectors, announced the appointment of Dr. Ram Palanki as Chairman of its Board of Directors.

Key Points: 
  • MILAN, ITALY / ACCESSWIRE / March 31, 2022 / AAVantgarde Bio , a Milan-based biotechnology start-up that is developing gene therapies for inherited retinal disorders based on Adeno-Associated Viral (AAV) vectors, announced the appointment of Dr. Ram Palanki as Chairman of its Board of Directors.
  • AAVantgarde Bio's technology builds on existing AAV platforms, which are the main viral vector technology used in gene therapy applications.
  • Existing AAV-based platforms have been limited by capacity, and AAVantgarde Bio is responding to this challenge by enabling delivery of large genes to tissue and cells in vivo.
  • Paola Pozzi, Partner in the Sofinnova Telethon Strategy and a member of the AAVantgarde Board of Directors, said: "We are thrilled to welcome Ram to AAVantgarde as Chairman of the Board.

Sensorion appoints Aniz Girach as Independent Board Member

Retrieved on: 
Tuesday, January 4, 2022

Sensorion (Paris:ALSEN) (FR0012596468 ALSEN), a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, announces that Aniz Girach, MD, is joining the Board of directors as an independent Board member.

Key Points: 
  • Sensorion (Paris:ALSEN) (FR0012596468 ALSEN), a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, announces that Aniz Girach, MD, is joining the Board of directors as an independent Board member.
  • His appointment will expand the number of independent Board members to four of a total of nine.
  • Were thrilled that Aniz has joined the Board of Sensorion.
  • Dr. Girach is an Honorary Professor at Wills Eye Hospital, Philadelphia, USA and a member of three Scientific Advisory Boards for international ophthalmic organizations.

AGTC Announces Two Key Leadership Team Appointments

Retrieved on: 
Thursday, October 14, 2021

Dr. Schneiders wealth of ophthalmology experience and impressive accomplishments bring valuable expertise to AGTCs leadership team.

Key Points: 
  • Dr. Schneiders wealth of ophthalmology experience and impressive accomplishments bring valuable expertise to AGTCs leadership team.
  • An ophthalmologist by training, her expertise in developing high performing ophthalmic therapeutic teams and building strong cross-functional programs will further strengthen AGTCs leadership in advancing their clinical stage assets.
  • AGTC is a leader in the field and working to meet important unmet medical needs in the ophthalmology community.
  • Additionally, AGTC is pleased to announce the appointment of Sarah C. DiSalvatore, M.P.H., as Vice President of Clinical Operations.